Načítá se...
Osimertinib as first-line therapy in advanced NSCLC: a profile of its use
Osimertinib (Tagrisso(®)) is an oral, CNS-active, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that selectively inhibits EGFR TKI-activating mutations over wild-type EGFR in patients with advanced non-small cell lung cancer (NSCLC), including the T790M mut...
Uloženo v:
| Vydáno v: | Drugs Ther Perspect |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer International Publishing
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6300577/ https://ncbi.nlm.nih.gov/pubmed/30631243 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40267-018-0536-9 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|